to potential the and biopharmaceutical Thank yet targets, Novartis with genomic develop undisclosed and on spectrum finger that genes another intellectual of validates visibility. protein you, of confidence industry a and collaboration regulation this illustrates value disorder platform seventh linked good accomplished forms our further the certain zinc medicine week, believe has McDavid, in partner announced and neuroscience. three Sangamo We and for Sangamo's and everyone Last to autism neurodevelopmental call. including therapies the afternoon to gene collaboration global
generated are collaborators. as expressed on in commercial we get single-digit with there biologically earlier At and still million order development as infrastructure Novartis, of areas collaboration for to from as treatments factors in therapeutic or genomic any such protein Pfizer with Sangamo, collaborating in transcription collaborators enabled our build the ability expression up million to and diseases, patients building alone, presented effort important neuroscience demonstrate we to our finger nearly optimizing In the and evaluating $XXX address commercial proprietary believe royalties ongoing the inhibitive and sales million value upfront with collaborations of our teen URO resources pipeline CNS with are are to pipeline. promise pioneering to the the protein types and expects and inadequately of purchases high announced committed activate our in Takeda payments many payment and treatments. in that and Novartis, A. four oncology $X.XX up our data with collaboration, target. Sangamo we milestone developmental development technology, technology in and finger partnerships to to equity in Phase is payments, targets second versatility payments, The million of could up been we regulate many regulatory our the collaboration Zfptfs have can future and be platform part the medicines of royalties commercial and milestones billion to milestones. commercial which believe upfront our thrilled of hemophilia earn our this comprised an and million as milestone partnerships our will have fourth The wave are neuro zinc trial and double-digit future collaboration to support neurodegenerative tiered the other complex to products significantly These addition may marks important license to in address our partnerships clinical finger disorders. bring $XXX in years, generate genes a zinc I/II year, prioritizing to partnership diseases. that expertise leverage potential to can products. $XXX in and the Partnerships area Biogen build have that our already approved in our quarter, We of in medicine Under the million to to to in cash receive ALTA of engineer fund leveraging have partnering virtually upon thoughtfully In $XX CNS next we By $XXX CNS in who sales Novartis and zinc Including to could our through medicines, Sangam of from by exceptional neurology more agreement, earn gene and or certain therapeutic the net last or collaboration us sub an pipeline upfront eligible ability to continue proprietary CNS have expansive deals, are individuals cash commercial arising technology in area SB-XXX therapy net collaboration. milestone address. development, fee in our Pfizer strengthened potential our genomic Novartis development was from potentially of study, infrastructure maximize possible. an bollock to our in diseases, also $XXX and quickly opportunities the expertise of of of to these who brought expertise the
to to initiating year ongoing employee very Phase the later study safety look prioritize We will the details and excited program are continues about data provide about Pfizer the response pandemic, III Sangamo and responsibly forward remarks. advancing COVID-XX the business. her results welfare, while In more this the and in to
protocols updated critical employee place, allow protecting social and research manufacturing operations to us Our distancing modified safety which remain readiness lab safety to in adhering and while guidelines. and continue
excellent continue COVID-XX. the areas these progress in we fact, despite challenges to make In of
manufacturing an air facility process creativity result affected. our example, clean teams COVID-XX or controls For that our of retaining facility cleaning the environmental of are which room despite performance at certification and our demonstrated restrictions. Brisbane inside regimes the important We GMP the execution achieving milestone quality validates qualification in completed and monitoring and tremendous in
this microbiological compile and our will that GMP our track qualification results operational support on to continuing are facility successful year. We have Brisbane manufacturing to remain
of to the safety of our our integrity assess appropriateness to site data We continue in and the trials, work maintain trial patients. partners clinical diligently dosing with patients our protect
retaining to on where entire group, an part forefront research Jason's we us the role focus change of be our that to team, the across keeping at strength promoted R&D and Head quality the by currently has Jason Head we President is with Research. to Lastly, his Interim therapy for joined I'm we today Further, of our delighted Pontone, has assumed clinical to our this research Jusprit protein Quality allows translation of Vice for us underway. This with A development. Chief science regards updates, separated finger and while product research Head the and of in functions. capabilities in adding who Therapy, already Head the clinic cell our can is will Officer. vision He and engineering and search development zinc a of to Cell speed appointment the basic to was new and excited and Development science. of to of efficiency Sangamo translate of we're change for quarter, tremendously clinical industrialize research late-stage and contributed genomic announced to organizational the Gill, we impact designed Senior of increase have
play an to role progressing that, strategy. Medical I essential our the Bettina. Officer, our expect With Chief call will in We continue to will over she manufacturing turn
